TRP_1170x120_12-19-19

Medivation

Pfizer to buy Medivation for $14 billion

Pfizer to buy Medivation for $14 billion

NEW YORK  — Boosting its oncology portfolio, Pfizer Inc. plans to acquire biopharmaceutical company Medivation for $14 billion in cash. Under the deal announced Monday, Pfizer is paying $81.50 a share in cash for San Francisco-based Medivation, whose products include XTANDI (enzalutamide), an androgen receptor inhibitor that the companies said is the nation’s leading novel